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Background: Stomatitis is a disturbing side-effect of chemotherapy that disturbs patients and causes difficulties in patient’s drinking, 
eating, and talking, and may results in infection and bleeding.
Objectives: This study aimed to investigate the effect of Yarrow distillate in the treatment of chemotherapy-induced stomatitis.
Patients and Methods: This randomized controlled trial study was conducted during 2013. The study population consisted of all cancer 
patients with chemotherapy-induced oral stomatitis referred to Shahid Beheshti Medical Center, Kashan, Iran. The data collection 
instrument had two-part; a demographic part and another part recording the severity of the stomatitis at the first, seventh, and 14th days 
of the intervention based on a WHO criteria checklist in 2005. In this study, 56 patients diagnosed with cancer were randomly assigned 
into control and experimental groups in similar blocks according to their stomatitis severity. The experimental group gargled 15 mL of 
a routine solution mixed with Yarrow distillate 4 times a day for 14 days while the control group gargled 15 mL of routine solution. The 
severity of stomatitis was assessed at the beginning of the intervention, and then after 7 and 14 days of the study. Data were analyzed using 
chi-square and Fisher exact test, Mann-Whitney U, Kruskal-Wallis statistic, and Friedman test using SPSS 11.5 software.
Results: At first, the median score of stomatitis in the experimental group was 2.50 that significantly reduced to 1 and 0 in days 7 and 14 of 
the intervention, respectively (P value < 0.001). However, in the control group, the median score of stomatitis was 2.50, which significantly 
increased to 3 in days 7 and 14, respectively (P value < 0.001).
Conclusions: Yarrow distillate-contained solution reduced stomatitis severity more than the routine solution. Therefore, we suggest 
using it in patients with chemotherapy-induced stomatitis.
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1. Background
Cancer is an important challenge for the healthcare sys-
tem (1, 2). Recent reports show that the rate of cancer is 
increasing with a fixed trend all over the world (1). Cancer 
has been known as the third major cause of mortality in 
Iran after the cardiovascular disease and accidents (3). 
Furthermore, it is the second cause of mortality in de-
veloped countries (4), and accounts for 13% to 25% of all 
deaths worldwide (1, 5).
Neoplasms are treated either to improve survival rate, 
or (if the treatment is impossible) to relief the symptoms, 
and to improve the quality of life. A combination of sur-
gery, radiotherapy, chemotherapy, and biological treat-
ments are usually used to achieve these objectives (2, 6). 
Chemotherapy is a common treatment that may result in 
longer periods of survival (7, 8). However, chemotherapy 
is accompanied with different problems; including bone 
marrow and immune system suppression; liver toxicity; 
complications in skin, central nervous system, urinary 
tract, and digestive tract such as inflammation of mouth 
and intestine mucosa (7, 8).
 Stomatitis or oral mucositis is a typical chemotherapy-
induced debilitating problem (9, 10) to such an extent 
that about 10% of the patients receiving adjuvant chemo-
therapy, 40% of the patients receiving neoadjuvant che-
motherapy, and 80% of the patients being treated with 
stem cells suffer from this problem (11-13). Stomatitis-
induced pain disturbs patients and makes it difficult to 
eat and drink, resulting in indigestion and dehydration 
(5, 9, 14). Stomatitis can also disturb speaking and com-
munication with others, resulting in psychological and 
social problems (1, 7, 8). In addition, stomatitis is accom-
panied by a wide range of oral mucosa alterations such 
as infection and bleeding, which could result in systemic 
infection (7, 8).
 In severe cases, it would increase the length of hospital-
ization and even make the physician to cease the chemo-
therapy (5, 9). Various methods and medications such as 
oral and dental hygiene, different types of mouthwash, 
applying ice and local anesthetics, magnesium-con-
tained antacids, diphenhydramine, nystatin, prostaglan-
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din E, granulocyte-macrophage colony-stimulating fac-
tor (GM-CSF), amphotericin, and chamomile essence are 
currently being used to treat stomatitis (2, 7, 8). Moreover, 
preventive measures are being taken, including receiv-
ing baking soda, normal saline, chlorhexidine, sucralfate, 
persica solution, allopurinol mouthwash, menthe distil-
late, and benzydamine solution (2, 7, 8, 15, 16). The most 
commonly used therapies often have no significant effect 
and sometimes cause additional problems (15). Given the 
side-effects of chemical drugs, complementary therapies 
in the forms of herbal products are increasingly used all 
over the world (17, 18).
 Most of the ancient civilizations used different forms 
of herbal medicines. The Yarrow plant (also called Ach-
illea millefolium) belongs to the Asteraceae family. It is 
a well-known herb and has been extensively used in an-
cient medicine for treating different diseases in general 
and burns and injuries in particular. One of the most 
important therapeutic effects of Yarrow plant  is its anti-
bacterial effect on a wide range of pathogens (19). Yarrow 
plant fresh flowers have been used to treat respiratory 
problems (20). It was also employed as an anti-allergic 
(21), anti-congestion, and expectorant medicine (22). Its 
flowers’ distillates contain chamazulene, cineol, and 
borneol (23) with anti-inflammatory and anti-spasmodic 
effects (24, 25), and also beneficial effects on nervous, car-
diovascular and digestive systems (21).
 Despite the historical background of this herb, reports 
about its therapeutic effects on wounds and injuries are 
rare (19). Aljancic et al. showed its significant inhibitory 
effect on Candida albicans and Bacillus subtilis in vitro. 
They also reported that, the flavonoids existed in Yarrow 
essence prevents the growth of Aspergillus niger (26). Sök-
men et al. have also studied the antimicrobial effects of 
Yarrow distillate on 12 bacterial species and 2 types of 
yeast. They have reported that its aqueous extract had 
no antibacterial activity, the methanol one and the herb 
distillate had considerable antimicrobial activity though 
(27), in another study, no significant difference was ob-
served in antimicrobial effects of aqueous and alcoholic 
extracts of Yarrow  (19).
2. Objectives
The researchers’ observations showed that cancer 
patients used Yarrow to alleviate their oral stomatitis. 
Therefore, the present study was designed to investigate 
the effect of Yarrow distillate-contained solution on the 
chemotherapy-induced stomatitis.
3. Patients and Methods
This was a triple-blind randomized trial study con-
ducted on patients suffering from cancer with chemo-
therapy-induced oral stomatitis referring to Shahid Be-
heshti Hospital in Kashan, Iran, during 2013. They were 
under chemotherapy and received an anti-inflammatory 
drug (Dexamethasone 8 mg) as well. In this study, the 
patients, physician, and nurses (who gave the medica-
tions) remained blind to the intervention outcomes and 
allocation of the subjects to the intervention and con-
trol groups. The physician who examined patients’ oral 
mucosa was also blind to the study and the intervention 
groups. In addition, the statistician who performed the 
data analysis was kept blinded to the allocation, as well.
Inclusion criteria were as follows: having chemother-
apy-induced oral stomatitis; ≤ 20 years; complete con-
sciousness; having no history of allergy, allergic rhinitis, 
and asthma; no history of radiotherapy; and not receiving 
systemic antibiotic and antifungal drugs. Exclusion crite-
ria were receiving radiotherapy during the study, fever, 
use of another mouthwash during the study, patient’s de-
cision to leave the study, irregular use of mouthwash in 
terms of time and amount, receiving systemic antibiotic 
or antifungal drugs at the beginning or during the study.
 The study sample size was calculated using the results 
of a local study conducted by Shabanloei et al. (2007), in 
which S1, S2, µ1, and µ2 were equal to 3.62, 6.95, 14.75, and 
3.18, respectively. Accordingly, with a type I error of 0.05 
and a power of 0.80, the sample size was determined to 
be seven patients for each group. However, for compen-
sating probable attritions and achieving more reliable 
results, we enrolled 28 patients for each group. Patients 
were recruited to the study by using the convenience 
sampling method. In the present study, 56 patients were 
selected based on the above-mentioned criteria and 
were randomly assigned into control and experimental 
groups in similar blocks based on stomatitis intensity. 
No patient was excluded, and no data missed during the 
study (Figure 1).
3.1. Intervention
The routine mouthwash was prepared by adding 1400 
mg of lidocaine, 224 mg of dexamethasone, 35000 mg of 
sucralfate per liter to diphenhydramine solution. The di-
phenhydramine solution was purchased from Alborz Da-
roo Company, Ghazvin, Iran. Control group received the 
routine mouthwash while the patients in the experimen-
tal group received a mixture of the routing mouthwash 
and Yarrow distillate (50/50). Both bottles were similar in 
shape and size, distinguished only by a special code (bot-
tle No. 1 and 2). The Yarrow distillate was prepared from 
the yarrow herb growing in the plains of Ardahal, Kashan, 
Iran by Barij Esans Company, Kashan, Iran. In order to pre-
pare 20 L of the distillate, 10 Kg of yarrow plant flowers 
with 50 L of water was boiled in a boiler connected to a 
condenser placed in cold water. The entire containers 
were from copper and the tubes from steel. The distillate 
used in this study had a concentration of 12 ppm.
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Enrollment
Assessed for aligibillity (n=56)
Excluded  (n=0)
Not meeting inclusion criteria (n=0)
Declied to participate (n=0)
Other reasons (n=0)
Randomized (n=56)
Allocation
Allocated to intervention (n=28) Allocated to intervention (n=28)
Follow-Up
Analysis
Lost to follow-up (n=0)
Discontinued intervention (n=0)
Lost to follow-up (n=0)
Discontinued intervention (n=0)
Analyzed (n=28)Analyzed (n=28)
Excluded from analyzes (n=0) Excluded from analyzes (n=0)
Figure 1. Consort Flow Diagram
All patients were trained individually, how to do mouth 
care, and use toothbrush and mouthwash. The patients 
were trained to wash their hands four times a day (after 
every meal: breakfast, lunch, dinner, and before going to 
bed) and brush their teeth with a soft toothbrush and 
toothpaste. According to the instruction, for 14 days, 
they had to hold 15 mL of the solution for 3 minutes in 
their mouth and then discard it. They were not allowed 
to wash their mouth or eat for an hour after mouth wash-
ing. To ensure proper mouthwash use, patients or one of 
their companions were trained to mark a checklist. The 
checklist had 14 columns (days) and each column with 
four rows (four times a day).
3.2. Data Collection
The data were collected using a two-part instrument. 
The first part consisted of demographic questions (age, 
gender, marital status, and education level), time of can-
cer, chemotherapy information (type, cycle's number in 
before intervention and during the study), receiving an 
analgesic, smoking habit and artificial teeth. The second 
part of the instrument was a checklist used to record the 
severity of stomatitis at the first, seventh and 14th days of 
the experiment. The severity of stomatitis was assessed 
based on WHO criteria (2005) as follows: grade 0 (no 
wound); grade 1 (pain and erythema); grade 2 (erythema 
and wound, but the patient could swallow solid foods); 
grade 3 (wound and extensive erythema, in this case the 
patient could not eat solid foods); grade 4 (stomatitis has 
been spread to an extent that it could not be treated eas-
ily and eating is impossible). The severity of stomatitis 
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was scored according to its grade (i.e. ranging from 0 to 
4). The content validity and reliability of the Persian ver-
sion of checklist were confirmed by Ashktorab et al., and 
its inter-observer reliability was 0.93 (28).
3.3. Ethical Considerations
The study was approved by the Research Council and 
Research Ethics Committee of Kashan University of Medi-
cal Sciences, No. P/29/5/1/2571 dated 16 Sep. 2013. The objec-
tives of the study were explained to all the participants, 
and all of them signed a written informed consent before 
participation in the study. All the patients were informed 
that participation in the study is voluntary and were as-
sured that their personal information would be treated 
confidentially. Researchers were committed to consider 
the participants rights in accordance to the principles ex-
plained in the Declaration of Helsinki.
3.4. Data Analysis
Data analysis was performed using SPSS version 11.5 
software (SPSS Inc., Chicago, IL, and The USA). Descrip-
tive statistics were used to describe and classify the 
data. Chi-square and Fisher exact tests were used to 
compare the two groups in terms of gender, marital 
status, education level, time of cancer, smoking habit, 
using false teeth, number of chemotherapy cycles be-
fore intervention and during the study and receiving 
an analgesic drug. The Shapiro-Wilk test showed that 
the distribution of data was not normal. Friedman (in 
each group) and Mann-Whitney U tests (between two 
groups) were used to compare the stomatitis severity at 
three times: At the onset, 7, and 14 days after intervention. 
Also, the Mann-Whitney U test was used to compare the 
mean scores of stomatitis severity in the two genders. 
Table 1. Demographic Information of the Cancer Patientsa
Variable Group P Value
Experimental Control
Gender 0.99b
Female 16 (57.1) 16 (57.1)
Male 12 (42.9) 12 (42.9)
Marital status 0.778b
Married 19 (67.9) 18 (64.3)
Single, Widow, Divorced 9 (32.1) 10 (35.7)
Education level 0.592b
Illiterate 14 (50) 12 (42.9)
Literate 14 (50) 16 (57.1)
False teeth 0.99b
Yes 17 (60.7) 17 (60.7)
No 11 (39.3) 11 (39.3)
Smoking habit 0.485b
Yes 4 (14.3) 6 (21.4)
No 24 (85.7) 22 (78.6)
Duration of Cancer, mo 0.763c
< 12 21 (75) 20 (71.4)
> 12 7 (25)  8 (28.6)
Chemotherapy cycles before intervention 0.946c
1-5 times  9 (32.1)  9 (32.1)
5-10 times 15 (53.6) 13 (46.4)
10-15 times  1 (3.6) 2 (7.1)
15-20 times  3 ( 10.7)  4 (14.3)
Chemotherapy cycles during the study 0.567b
1 time 20 (71.4) 18 (64.3)
2 times 8 (28.6) 10 (35.7)
Receiving an Analgesic 0.99c
Yes 5 (17.8) 5 (17.8)
No 51 (82.2) 51 (82.2)
a All data are presented as No. (%).
b chi-square.
c Fisher exact test.
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Control Experimental Control Experimental Control Experimental
Day 14 after receiving
mouthwash
Day 7 after receiving
mouthwash
Before intervention
Grade 4
Grade 3
Grade 2
Grade 1
Grade zero 
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
32.1
32.1
32.1
32.1 32.1
28.6
28.6
7.1 7.1
7.1 7.1
25
71.4
42.9 42.9
39.3
39.3
3.6 3.6
17.9 17.9
21.4
28.6
Figure 2. Comparison of the Severity of Stomatitis in Three Observations
Table 2. Comparison of Average Stomatitis Severity Scores in 
Three Observations
Severity of 
stomatitis
Group P Valuea Z Value
Control Experimental
Median (Q3-Q1) Median (Q3-Q1)
Before 
intervention
2.50 (3-2) 2.50 (3-2) 1 0.000
Day 7 after 
receiving 
mouthwash
3 (3-2) 1 (2-0) 0.001 -5.26
Day 14 after 
receiving 
mouthwash
3 (4-2) 0 (1-0) 0.001 -6.41
P valueb 0.001 0.001 - -
a Mann-Whitney U test.
b Friedman test.
The Spearman correlation coefficient was also used to 
evaluate the relationship between stomatitis severity 
and age. A P value less than 0.05 was considered signifi-
cant for all tests.
4. Results
Totally, 56 patients participated in this study was 56. No 
significant difference was observed in terms of average 
age between the experimental (56.46 ± 14.32 y) and con-
trol group (55.54 ± 14.01 y) (P = 0.807). In total, 67.9% of the 
experimental group and 64.3% of the control group were 
married. There was no significant difference regarding 
false teeth, smoking habit, and other demographic infor-
mation between the two groups (Table 1). The Spearman 
correlation coefficient showed no significant relation-
ship between stomatitis severity and age (P value > 0.05). 
Also, the Mann-Whitney U test certified that gender had 
no effect on stomatitis severity before or during the study 
(P value > 0.05).
Before receiving the solutions, 42.9% and 32.1% of the 
patients in control and experimental groups had grade 3 
and 2 stomatitis, respectively (Figure 2). The median score 
of stomatitis severity was equal (2.50) in both groups at 
the start of the study. The median scores of stomatitis in 
the experimental group significantly reduced to 1 and 
0 in days 7 and 14 after the intervention, respectively (P 
value < 0.001). However, in the control group, the median 
score of stomatitis increased to 3 in days 7 and 14 (P value 
< 0.001) (Table 2).
5. Discussion
The present study was designed to investigate the effect 
of Yarrow distillate on chemotherapy-induced stomatitis. 
In this study, the stomatitis severity was significantly re-
duced in the experimental group receiving the solution 
contained Yarrow distillate. It was interesting to see that, 
more than 71% of the patients in this group were com-
pletely cured on 14th day of the experiment. Abedipour 
et al. have compared the effects of chlorhexidine and 
persica mouthwash -that contains A. millefolium- on 
preventing stomatitis in patients receiving chemother-
apy and reported that both mouthwashes had similar 
effects. However, due to its better taste and smell, they 
recommended persica mouthwash as an alternative for 
chlorhexidine (7). Using different solutions and different 
forms of plant might be the reason for the different re-
sults seen between their study and ours i.e. we used Yar-
row distillate in our routine mouthwash, but they used 
the extract of Yarrow in chlorhexidine solution. 
Mozaffari et al. have shown that Yarrow distillate was ef-
fective in treatment of rats’ gastric ulcer. This effect was 
attributed to the antibacterial and healing properties of 
Yarrow (29). Among herbal plants, Yarrow has gained at-
tentions due to its wide range of therapeutic effects. It is a 
known herb, which has been used for thousands of years 
for treatment of different disorders, especially wounds 
and infections. Researches indicate that the essential oil 
of the herb has inhibitory effects on various bacteria (21, 
25). According to Aljancic et al. (1999), the flavonoids in 
Yarrow essence have antifungal effect (26). Some flavo-
noids (i.e. rutin, apigenin, luteolin, and acacetin) and 
bioactive ingredients of Yarrow (i.e. caffeic acid and sali-
cylic acid) have antibacterial and anti-inflammatory ef-
fects (21, 25, 30). Sökmen et al. (2003) have extracted 32 
separate ingredients from Yarrow, among which cam-
phor and eucalyptol have significant inhibitory effects 
on Candida albicans and Clostridium perfringens. Also, 
borneol and piperitone in Yarrow essence are two other 
compounds with considerable bacterial inhibitory activ-
ity (31). This antibacterial and anti-fungal effect of Yarrow 
might be one of the reasons for the results we had in our 
experiment.
 The routine mouthwash used in cancer clinics did not 
show any significant effect on the chemotherapy induced 
stomatitis in our study. In the present study, stomatitis 
severity increased in the control group during the experi-
ment. In the control group, the number of the patients 
with grade 4 stomatitis increased from 7.1% to 21.4% on 
seventh and to 32.1% on 14th day of the experiment. The 
total percent of grade 3 and 4 was increased on seventh 
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and 14th days of the experiment in control group as well. 
Clarkson et al. (2008), have reported that although allo-
purinol, granulocyte growth factors, immunoglobulin 
and herbal extracts are effective but sucralfate, lidocaine, 
or diphenhydramine had no effect in treating chemo-
therapy-induced stomatitis (32).
Since the mixture of Yarrow distillate with the routine 
solution used in this study could decrease the severity of 
stomatitis after chemotherapy and had no side effects, 
this solution might be used for all patients during che-
motherapy. Given that the Yarrow distillate was mixed 
with ward’s routine solution, it is suggested that Yarrow 
distillate be used alone to clearly define its effect on sto-
matitis improvement. Also the mixture of Yarrow distil-
late with other types of mouthwash should be tested to 
optimize the effect of this plant.
Some limitations are accounted for this study. For ex-
ample, the patients took the solutions at home where 
the researcher had no control over them. Moreover, the 
small sample size, disregarding other variables such as 
teeth problems (decay, break, and implant), history of 
oral disease, and white blood cell (WBC) count may limit 
the generalizability of the findings. Also, it would be bet-
ter if the patients’ mouths were checked daily in order to 
determine the treatment progress.
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